Shots:
- Morphic will receive a $20M as license fee and is eligible to receive milestones and royalties on sales of any commercialized therapy while AbbVie has exercised a license option under the companies’ R&D collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors for fibrotic diseases including IPF and additional indications
- The license covers αvβ6 integrin inhibitors including MORF-720 and MORF-627, supported by an extensive preclinical data demonstrating potential as treatments for IPF as well as other fibrotic diseases
- Under the original deal, Morphic would handle R&D work on its pipeline through IND-enabling studies, after which AbbVie has an option to take each compound for global development and commercialization
Click here to read full press release/ article | Ref: AbbVie | Image: WSJ
